Dose specification of Dopamine agonist, pergoline: Treatment in a cohort of subfertile Iraqi women with asymptomatic hyperprolactinemia: A prospective study

Abstract

Infertility is an important problem experienced by a significant proportion of couples in the population. Hyperprolactinemia is a key finding in a subset of women with primary and secondary infertility. Pergoline has been investigated by many authors to reduce serum prolactin and to increase ovarian follicle size; however, significant controversy is present in the available literature to justify conductance of the present study. This study was aimed to evaluate the role of pergoline treatment in a subset of subfertile Iraqi women on both ovarian follicle size and serum prolactin level. The current study involved 60 subfertile women who were treated with pergoline at a dose of 2.5 mg every 3 days for 8 weeks. Baseline estimation of serum prolactin and ovarian follicle size at luteal phase was performed and the second reading of these variables was conducted 8 weeks after treatment. The study was carried out in Al-Diwaniyah maternity and child teaching hospital in Al-Diwaniyah province, Iraq. The study was started at August 2016 and extended through January 2018. The results revealed that after 8 weeks from regular treatment with pergoline, serum prolactin was highly significantly reduced from 64 (45) ng/ml to 30.4 (24) ng/ml (P <0.001). In addition, it was found that the follicle size was highly significantly increased from 10 (2) mm to 17.5 (4.75) mm (P<0.001). It has been concluded that pergoline is an effective mode of treatment to treat subfertile women with asymptomatic hyperprolactinemia and to increase the size of growing ovarian follicles.